Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization expense for intangible assets	$ 2,400	$ 2,000	$ 2,100
Licenses and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets	3,091	3,212
Koselugo | Licenses and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets	49
Lynparza | Licenses and other
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intangible assets	1,200
AstraZeneca
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amortization expense for intangible assets	48		250
AstraZeneca | Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable contingent payments	100
Liabilities	100
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments sales-based			400
Probable contingent payments			600
Liabilities			600
Sales milestone payments	2,000
Regulatory milestone payments	$ 245	$ 105	$ 250